Analysts Set Expectations for GeoVax Labs FY2024 Earnings

GeoVax Labs, Inc. (NASDAQ:GOVX) – Roth Capital increased their FY2024 earnings per share estimates for GeoVax Labs in a research note issued on Tuesday, November 12th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($4.30) per share for the year, up from their prior estimate of ($5.52). The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.10) per share. Roth Capital also issued estimates for GeoVax Labs’ Q4 2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $8.55 EPS.

Several other research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research note on Friday. Noble Financial boosted their price target on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, August 19th. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Finally, Alliance Global Partners started coverage on GeoVax Labs in a report on Monday, November 11th. They issued a “buy” rating and a $15.00 target price for the company. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $13.25.

GeoVax Labs Stock Down 6.9 %

Shares of GOVX opened at $2.43 on Friday. The firm’s 50 day moving average price is $2.39 and its 200 day moving average price is $2.59. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The firm had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period last year, the business earned ($4.80) earnings per share.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.